Focused On-demand Library for Small ribosomal subunit protein uS2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P08865

UPID:

RSSA_HUMAN

Alternative names:

37 kDa laminin receptor precursor; 37/67 kDa laminin receptor; 40S ribosomal protein SA; 67 kDa laminin receptor; Colon carcinoma laminin-binding protein; Laminin receptor 1; Laminin-binding protein precursor p40; Multidrug resistance-associated protein MGr1-Ag; NEM/1CHD4

Alternative UPACC:

P08865; P11085; P12030; Q16471; Q6IPD1; Q6IPD2; Q6NSD1; Q6NXQ8; Q86VC0

Background:

Small ribosomal subunit protein uS2, known as the 40S ribosomal protein SA, plays a crucial role in the assembly and stability of the 40S ribosomal subunit. It is essential for processing the 20S rRNA-precursor into mature 18S rRNA, a key step in ribosomal subunit maturation. Additionally, it serves as a cell surface receptor for laminin, influencing cell adhesion, signaling pathways, and tissue morphogenesis. Its interaction with various pathogens, including Adeno-associated viruses, Dengue virus, and the pathogenic prion protein, highlights its significance in microbial infection.

Therapeutic significance:

Given its involvement in isolated congenital asplenia, a rare and life-threatening condition, understanding the role of Small ribosomal subunit protein uS2 could open doors to potential therapeutic strategies. Its pivotal role in ribosomal function and cell surface interactions makes it a target for addressing severe bacterial infections and possibly influencing tissue morphogenesis and disease outcomes.